论文部分内容阅读
致病菌对抗生素持续增长的耐药性与抗生素广谱杀菌对人类健康带来的长久负面影响,使开发不同治疗机制的抗菌药物成为人类维护健康的一个紧迫话题,而抗体类药物以其靶向性与高效性进入了人们的视野。目前全球抗菌抗体药物既有已经上市的治疗吸入性炭疽病的瑞西巴库,也有众多的以治疗金黄色葡萄球菌与铜绿假单胞菌感染为代表的处于临床阶段或临床前阶段的抗体药物。在研抗菌抗体药物通常的作用靶点是致病菌侵袭力物质基础与相关毒素,抗体工程技术的发展,如基因工程小鼠、抗体库、人杂交瘤细胞及单个B细胞抗体制备技术等在抗菌抗体药物的研发中也发挥着重要的促进作用。抗菌抗体药物或将成为精准治疗细菌感染的靶向药物,为人类健康事业贡献力量。
The long-term negative effects of pathogenic bacteria on antibiotics and broad-spectrum antibiotics antibacterials on human health have made the development of antimicrobial agents with different therapeutic mechanisms a pressing issue for human health, and their use as targets The direction and efficiency into the people’s vision. At present, the world’s antimicrobial antibody drugs are already available on the market, such as Ruixi Baku for the treatment of inhalation anthracnose, and a large number of antibody drugs in the clinical or preclinical stages, such as the treatment of Staphylococcus aureus and Pseudomonas aeruginosa infections . Antibacterial antibody drugs in the study of the general target of pathogens is the basis of invasive substances and related toxins, antibody engineering and technology development, such as genetically engineered mice, antibody library, human hybridoma cells and single B cell antibody preparation techniques Antibacterial antibody drug development also plays an important role in promoting. Antimicrobial antibody drugs or drugs will be targeted to accurately treat bacterial infections, contribute to the cause of human health.